Provided by Tiger Trade Technology Pte. Ltd.

BRII-B

1.030
+0.0201.98%
Volume:373.00K
Turnover:372.82K
Market Cap:743.66M
PE:-2.86
High:1.030
Open:1.015
Low:0.970
Close:1.010
52wk High:2.340
52wk Low:0.900
Shares:722.00M
HK Float Shares:722.00M
Volume Ratio:0.32
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.360
ROE:-7.67%
ROA:-6.42%
PB:0.29
PE(LYR):-2.86
PS:11.12

Loading ...

Brii Bio Repurchases 120,000 Shares; Treasury Stock Rises to 12.90 Million

Bulletin Express
·
Yesterday

Brii-Biosciences (BRII-B) Issues 0.26 Million New Shares Under Employee Schemes; Repurchases 0.06 Million Shares Into Treasury

Bulletin Express
·
Aug 24

BRII-B (02137) Buys Back 60,000 Shares for HK$60,300 on August 24

Stock News
·
Aug 24

Brii Biosciences Files HKEX Next-Day Disclosure, Lifts Share Capital by 255,793 Shares

Reuters
·
Aug 24

Sinopharm Interim Revenue Edges Down on Softness in Pharmaceutical Distribution Business

Reuters
·
Aug 24

Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook

Reuters
·
Aug 22

Biotech Firm Antengene's H1 Revenue Jumps on Licensing Deals

Reuters
·
Aug 21

Hong Kong Stock Market Flash: BRII-B Surges Over 8% as Interim Loss Narrows 32.08% and Promising Clinical Data Emerges

Stock News
·
Aug 21

China's Brii Biosciences Interim Net Loss Narrows on Lower R&D Expenses

Reuters
·
Aug 21

Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results

THOMSON REUTERS
·
Aug 21

Brii Biosciences: Hy Other Income Rmb19.5 Mln

THOMSON REUTERS
·
Aug 21

Brii Bio H1 FY26 Loss Narrows 32.1% to RMB 101 Million

Reuters
·
Aug 21

Brii Biosciences Sets 20 August 2026 Board Meeting to Review 1H26 Interim Results

Bulletin Express
·
Aug 07

Brii Biosciences Schedules Board Meeting to Review Interim Results

Reuters
·
Aug 07

Analyzing the First Half Fiscal Revenue and Expenditure Growth Rates in 2026

Deep News
·
Jul 29

Brii Biosciences (BRII-B) Adds 46.56 Thousand New Shares in June; Confirms Public-Float Compliance

Bulletin Express
·
Jul 07

Is Brii Biosciences (HKG:2137) In A Good Position To Deliver On Growth Plans?

Simply Wall St.
·
Jul 04

Brii Bio Announces Topline End-of-treatment Data from Phase 2B Enrich and Enhance Studies for the Treatment of Chronic Hepatitis B

THOMSON REUTERS
·
Jul 03

BRII-B Reports End-of-Treatment Topline Data from Phase 2b ENRICH and ENHANCE Studies for Chronic Hepatitis B

Stock News
·
Jul 03

Brii Biosciences Says Arbitration with Vir Clouds Future of Elebsiran Program

Reuters
·
Jul 03